SCHEMBL26427359

SCHEMBL26427359

Cc1c(C)c(C)c2c(c1C)CC[C@@](C)(CO)O2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 2/20 0.48
MAPT P10636 2/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
USP2 O75604 2/20 0.46
CYP2C9 P11712 2/20 0.46
GSTP1 P09211 1/20 0.46
TTPA P49638 1/20 0.46
THRB P10828 1/20 0.46
CYP2C19 P33261 1/20 0.46
ALOX5 P09917 5/20 0.44
CYP3A4 P08684 2/20 0.43
TSHR P16473 2/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
CYP1A2 P05177 1/20 0.43
PDE4A P27815 1/20 0.41
PDE3A Q14432 1/20 0.41
GSTO1 P78417 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15150901 1.00 NR1I2 (0.48) NR1I2MAPTLMNAMEN1KMT2A
SCHEMBL26427552 1.00 NR1I2 (0.48) NR1I2MAPTLMNAMEN1KMT2A
SCHEMBL5672019 0.88 NR1I2 (0.61) NR1I2MAPTLMNAMEN1KMT2A
SCHEMBL2176872 0.88 NR1I2 (0.61) NR1I2MAPTLMNAMEN1KMT2A
SCHEMBL5672022 0.88 NR1I2 (0.61) NR1I2MAPTLMNAMEN1KMT2A
SCHEMBL20819441 0.87 NR1I2 (0.44) NR1I2MAPTLMNAMEN1KMT2A
SCHEMBL20819442 0.87 NR1I2 (0.44) NR1I2MAPTLMNAMEN1KMT2A
SCHEMBL9632542 0.81 PSEN1 (0.45) NR1I2MAPTLMNAMEN1KMT2A
SCHEMBL3941352 0.81 NR1I2 (0.40) NR1I2MAPTLMNAMEN1KMT2A
SCHEMBL8376060 0.81 MEN1 (0.64) NR1I2MEN1KMT2ATTPAALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303506-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA STEALTH BIOTHERAPEUTICS INC. (US) 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303506-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA FH, COQ8A, TFAM NR1I2 2989/4885MAPT 1057/4885LMNA 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.